GeNeuro S.A.
GNRRF
Other OTC4.55
USD
- -
- -
GeNeuro S.A.
GNRRF
(Other OTC)
Recent
price
4.55
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- GeNeuro S.A. operates as a clinical-stage biopharmaceutical entity, primarily engaged in developing innovative therapeutics for severe neurodegenerative and autoimmune conditions. Its central investigational compound, temelimab, a humanized monoclonal antibody designed to neutralize the pathogenic HERV-W envelope protein, has successfully completed Phase II clinical evaluations for multiple sclerosis. The company is actively seeking new partnerships to advance its lead multiple sclerosis program. In addition to its work in multiple sclerosis, GeNeuro had pursued temelimab in a Phase II study for neuropsychiatric symptoms associated with long-COVID. While patient enrollment concluded in late 2023, the trial announced disappointing outcomes in June 2024, indicating no significant clinical benefit on primary or most secondary endpoints, which led to significant organizational restructuring. Earlier efforts also included a Phase IIa program for type 1 diabetes, which has since been put on hold to concentrate resources on other key areas. Furthermore, the pipeline includes GNK301, a preclinical candidate targeting the HERV-K envelope protein for sporadic amyotrophic lateral sclerosis. The company engages in various research and development collaborations, notably with the National Institute of Neurological Disorders and Stroke for new antibody programs against HERV-K Env in ALS, and previously with the FondaMental Foundation and Northwestern University for insights into HERV-W Env's role in post-COVID patients. Following recent clinical setbacks, GeNeuro has undertaken a substantial restructuring effort, including workforce reductions and the liquidation of its French subsidiary in mid-2025. The company has also secured and extended debt-restructuring moratoriums to address its financial position and explore strategic alternatives, including asset monetization. Established in 2006, the firm maintains its headquarters in Plan-les-Ouates, Switzerland.